Business Description
CRISPR Therapeutics AG
ISIN : CH0334081137
Share Class Description:
LTS:0VRQ: Ordinary SharesDescription
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.51 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.73 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.53 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 735.7 | |||||
| 3-Year EBITDA Growth Rate | 21.2 | |||||
| 3-Year EPS without NRI Growth Rate | 28.4 | |||||
| 3-Year FCF Growth Rate | 4.1 | |||||
| 3-Year Book Growth Rate | 1.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.02 | |||||
| 9-Day RSI | 27.16 | |||||
| 14-Day RSI | 32.27 | |||||
| 6-1 Month Momentum % | -18.74 | |||||
| 12-1 Month Momentum % | -25.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.64 | |||||
| Quick Ratio | 21.64 | |||||
| Cash Ratio | 21.55 | |||||
| Days Sales Outstanding | 246.38 | |||||
| Days Payable | 59.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -7.9 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.88 | |||||
| Operating Margin % | -166.2 | |||||
| Net Margin % | -119.8 | |||||
| FCF Margin % | -95.6 | |||||
| ROE % | -12.46 | |||||
| ROA % | -10.55 | |||||
| ROIC % | -91.77 | |||||
| ROC (Joel Greenblatt) % | -102.95 | |||||
| ROCE % | -15.4 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.31 | |||||
| PB Ratio | 1.8 | |||||
| Price-to-Tangible-Book | 1.82 | |||||
| EV-to-EBIT | -5.38 | |||||
| EV-to-Forward-EBIT | -4.54 | |||||
| EV-to-EBITDA | -5.71 | |||||
| EV-to-Forward-EBITDA | -4.58 | |||||
| EV-to-Revenue | 8.94 | |||||
| EV-to-Forward-Revenue | 15.6 | |||||
| EV-to-FCF | -9.14 | |||||
| Price-to-Projected-FCF | 7.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.18 | |||||
| Price-to-Net-Cash | 2.19 | |||||
| Earnings Yield (Greenblatt) % | -18.59 | |||||
| FCF Yield % | -5.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CRISPR Therapeutics AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 200 | ||
| EPS (TTM) ($) | -2.8 | ||
| Beta | 0.24 | ||
| Volatility % | 49.2 | ||
| 14-Day RSI | 32.27 | ||
| 14-Day ATR ($) | 2.181182 | ||
| 20-Day SMA ($) | 47.45087 | ||
| 12-1 Month Momentum % | -25.23 | ||
| 52-Week Range ($) | 39.4 - 91 | ||
| Shares Outstanding (Mil) | 85.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CRISPR Therapeutics AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CRISPR Therapeutics AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CRISPR Therapeutics AG Frequently Asked Questions
What is CRISPR Therapeutics AG(LTS:0VRQ)'s stock price today?
The current price of LTS:0VRQ is $40.88. The 52 week high of LTS:0VRQ is $91.00 and 52 week low is $39.40.
When is next earnings date of CRISPR Therapeutics AG(LTS:0VRQ)?
The next earnings date of CRISPR Therapeutics AG(LTS:0VRQ) is 2025-02-21 Est..
Does CRISPR Therapeutics AG(LTS:0VRQ) pay dividends? If so, how much?
CRISPR Therapeutics AG(LTS:0VRQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers